slides · global inventory
List
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 110,471
Current window 86,941-86,970
Pages 3,683
Rows per page 30
Component
86,941-86,970 of 110,471
12
The slide uses a process flow diagram to explain the 'zero-shot' capability of their AI platform.Absci | Investor Presentation Deck | 37 slides · Absci
Pitch deck Investor relations Beat · Solution1 hit
14
The chart shows binding affinity (-log10(Kd)) vs sequence diversity (edit distance to trastuzumab) across search spaces ranging from millions to quadrillions.Absci | Investor Presentation Deck | 37 slides · Absci
Pitch deck Investor relations Beat · TractionLoop · Before After1 hit
15
The chart is a dot plot showing naturalness score vs sequence diversity, with a red dashed line representing the wildtype baseline.Absci | Investor Presentation Deck | 37 slides · Absci
Pitch deck Investor relations 1 hit
17
Uses a Venn diagram to represent the intersection of three properties optimized by AI.Absci | Investor Presentation Deck | 37 slides · Absci
Pitch deck Investor relations 1 hit
19
The chart shows a histogram of binding affinity (-log10(KD)) for designed variants compared to the wild-type Trastuzumab baseline.Absci | Investor Presentation Deck | 37 slides · Absci
Pitch deck Investor relations 1 hit
22
Includes a biological diagram of TLS and a Kaplan-Meier survival curve.Absci | Investor Presentation Deck | 37 slides · Absci
Pitch deck Investor relations 1 hit
24
The pie chart labels are slightly ambiguous; the 26% slice is labeled 'Immuno-oncology', 39% 'Oncology', and 35% 'Autoimmunity and Inflammation'.Absci | Investor Presentation Deck | 37 slides · Absci
Pitch deck Investor relations 1 hit
26
The slide illustrates the mechanism of incorporating non-standard amino acids into antibodies for ADC development.Absci | Investor Presentation Deck | 37 slides · Absci
Pitch deck Investor relations 1 hit
28
Case study showing molecular weight validation of protein expression.Absci | Investor Presentation Deck | 37 slides · Absci
Pitch deck Investor relations 1 hit
29
The slide uses a four-column layout to categorize value propositions, each supported by a small icon or diagram.Absci | Investor Presentation Deck | 37 slides · Absci
Pitch deck Investor relations 1 hit
30
PoS stands for Probability of Success. The slide uses a comparative timeline framework to illustrate efficiency gains.Absci | Investor Presentation Deck | 37 slides · Absci
Pitch deck Investor relations 1 hit
03
Advantage Solutions | Investor Presentation Deck | 27 slidesAdvantage Solutions | Investor Presentation Deck | 27 slides · Advantage Solutions
Pitch deck Investor relations Beat · Problem1 hit
08
The slide uses a donut chart to illustrate market dominance.Advantage Solutions | Investor Presentation Deck | 27 slides · Advantage Solutions
Pitch deck Investor relations Beat · Market Size1 hit
27
This is the final page of a 6-part appendix section detailing financial adjustments.Advantage Solutions | Investor Presentation Deck | 27 slides · Advantage Solutions
Pitch deck Investor relations 1 hit
12
This is the fourth page of a four-part appendix disclosure regarding non-GAAP financial measures.Advantage Solutions | Results Presentation Deck | 13 slides · Advantage Solutions
Conference presentation Investor relations Beat · Appendix1 hit
09
Includes two testimonials from Key Opinion Leaders (KOLs) to emphasize the difficulty of treatment compliance.Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Problem1 hit
10
The slide uses a pie chart for segmentation and a timeline/number line for diagnostic age, followed by key clinical metrics.Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · AgitateLoop · Mece Breakdown1 hit
12
The chart shows a clear dose-response relationship between 1.0 mg/kg and 10.0 mg/kg doses, with statistical significance marked at early time points.Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution1 hit
21
The slide uses a heatmap to visualize individual patient outcomes, a common technique in clinical trial reporting.Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
22
Data presented as n (%).Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
33
The slide uses a box plot to visualize longitudinal clinical trial data.Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
04
Aeva | Results Presentation Deck | 14 slidesAeva | Results Presentation Deck | 14 slides · Aeva
Shareholder letter Investor relations 1 hit
08
Uses a 2x2-style quadrant map to illustrate competitive advantage.Aeva | Results Presentation Deck | 14 slides · Aeva
Shareholder letter Investor relations Loop · Aha Moment1 hit
09
Aeva | Results Presentation Deck | 14 slidesAeva | Results Presentation Deck | 14 slides · Aeva
Shareholder letter Investor relations Loop · Aha Moment1 hit
03
Hub-and-spoke diagram showing core business pillars.Alkermes | Investor Presentation Deck | 32 slides · Alkermes
Research note Investor relations Beat · Situation & ContextLoop · Golden Circle1 hit
05
Alkermes | Investor Presentation Deck | 32 slidesAlkermes | Investor Presentation Deck | 32 slides · Alkermes
Research note Investor relations Beat · Impact & Next StepsLoop · Golden Circle1 hit
07
Includes a boxed warning disclaimer at the bottom.Alkermes | Investor Presentation Deck | 32 slides · Alkermes
Research note Investor relations 1 hit
12
Alkermes | Investor Presentation Deck | 32 slidesAlkermes | Investor Presentation Deck | 32 slides · Alkermes
Research note Investor relations Beat · Evidence & Proof1 hit
13
Includes product branding, dosage options, and a bar chart showing revenue growth.Alkermes | Investor Presentation Deck | 32 slides · Alkermes
Research note Investor relations Beat · Evidence & Proof1 hit
14
Includes a callout regarding COVID-19 impact on 2020 sales.Alkermes | Investor Presentation Deck | 32 slides · Alkermes
Research note Investor relations Beat · Evidence & Proof1 hit